U.S. markets close in 56 minutes
  • S&P 500

    4,419.09
    +7.30 (+0.17%)
     
  • Dow 30

    35,122.99
    +61.44 (+0.18%)
     
  • Nasdaq

    14,839.15
    +2.16 (+0.01%)
     
  • Russell 2000

    2,214.18
    +4.54 (+0.21%)
     
  • Crude Oil

    72.18
    +0.11 (+0.15%)
     
  • Gold

    1,796.90
    -4.90 (-0.27%)
     
  • Silver

    25.25
    +0.02 (+0.07%)
     
  • EUR/USD

    1.1805
    +0.0035 (+0.30%)
     
  • 10-Yr Bond

    1.2780
    -0.0080 (-0.62%)
     
  • GBP/USD

    1.3814
    +0.0060 (+0.44%)
     
  • USD/JPY

    110.3620
    -0.1480 (-0.13%)
     
  • BTC-USD

    39,701.88
    +5,267.51 (+15.30%)
     
  • CMC Crypto 200

    943.65
    +28.16 (+3.08%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

Impax commenced shipment of authorized generic Zomig

Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013.